Regulation (EU) 2023/11822023/0064(COD)COM(2023)122

Specific rules relating to medicinal products for human use intended to be placed on the market of Northern Ireland

Stage: In force, reached 20 Jun 2023
In force: In force since 21 Jun 2023 · CELEX 32023R1182
Procedure: Ordinary legislative procedure
Rapporteur: Pascal Canfin (Renew)
Lead DG: DG SANTE
Last activity: 20 Jun 2023

15 entries · record as of 14 Sept 2026

Where it stands

Latest: Published in the Official Journal, 20 Jun 2023.

Show the earlier record: 6 dates, 27 Feb 2023 to 9 May 2023

27 Feb 2023
- Adoption by Commission
28 Feb 2023
- Discussions within the Council or its preparatory bodies
3 Mar 2023
- Discussions within the Council or its preparatory bodies
13 Mar 2023
- Referred to committee
19 Apr 2023
- Discussions within the Council or its preparatory bodies
9 May 2023
- Plenary adopted first-reading position
- Plenary vote results

15 May 2023
- Discussions within the Council or its preparatory bodies
16 May 2023
- Discussions within the Council or its preparatory bodies
17 May 2023
- Discussions within the Council or its preparatory bodies
22 May 2023
- Discussions within the Council or its preparatory bodies
30 May 2023
- Approval of the EP's first reading position by the Council (adoption of the legislative act)
12 Jun 2023
- Plenary sitting
14 Jun 2023
- Signed
20 Jun 2023
- Published in the Official Journal

7 people

Who is on it

The Parliament's rapporteurs, shadow rapporteurs and opinion rapporteurs currently on this file.

Role	Name	Group	Country	Committee
Rapporteur	Pascal Canfin	Renew	FR	ENVI
Shadow rapporteur	Alexandr Vondra	ECR	CZ	ENVI
Shadow rapporteur	Bas Eickhout	Greens/EFA	NL	ENVI
Shadow rapporteur	Beatrice Covassi	S&D	IT	ENVI
Shadow rapporteur	Deirdre Clune	EPP	IE	ENVI
Shadow rapporteur	Idoia Villanueva Ruiz	The Left	ES	ENVI
Shadow rapporteur	Silvia Sardone	PfE	IT	ENVI

9 documents

Documents

Newest first. Each opens at its source.

Report · A9-0167/2023Parliament
Proposal · COM(2024)0565Parliament
Text adopted · OJ L 157 20.06.2023, p. 0001Commission
Report · PE745.428Parliament
Amendments · PE745.507Parliament
Committee opinion · PE746.888Parliament
Text adopted · Regulation 2023/1182Commission
Text adopted · SP(2023)273Parliament
Text adopted · T9-0122/2023Parliament

Summary

Generated

This regulation ensures the continued supply of human medicines to Northern Ireland by aligning EU rules with the Windsor Framework's provisions. It primarily affects pharmaceutical companies, regulators, and healthcare providers operating in or supplying the Northern Irish market. The act was signed in June 2023 and is now in force.

What the workspace adds on this file

Everything above is the public record. Subscribers see this page with their own layer on top.

Why it matters to you

What this file means for your organization, assessed against your own priorities.

What moved

When this file moves, it reaches your own briefing, with a link to its source.

Your contacts on it

Your team's contacts logged against this file: who you met, what was said and the next step.

A first draft

A statement, a member update or a meeting brief on this file, in your organization's voice, with its sources.

Sources: EP Legislative Observatory · EUR-Lex. Record as of 14 Sept 2026. Something wrong on this page? Report an error.

Request access

See this file with your own layer on top: why it matters to you, your contacts on it and a first draft. We’ll schedule a 20-minute walkthrough.

EU-hosted · GDPR-compliant · Trust Center →

By submitting, you agree to our privacy policy.